Bronchiolitis
Conditions
Keywords
Bronchiolitis, Vitamin D, Children
Brief summary
Vitamin D plays an important role in enhancing mucosal immune defense, decreasing excessive inflammation, and increasing mucociliary clearance. Experimental studies have shown that vitamin D reduces inflammation of epithelial cells in airways infected with Respiratory Syncytial Virus and confers antiviral effects. Furthermore, several studies have shown lower serum vitamin D levels in hospitalized children with bronchiolitis. However, studies on the efficacy of Vitamin D supplementation for children with bronchiolitis are scarce with inconsistent findings. In this study, we aim to evaluate the efficacy of vitamin D supplementation in children with bronchiolitis.
Detailed description
Bronchiolitis is the most frequent lower respiratory tract infection in children under two years of age, which represents a major cause of medical visits, hospital admissions, and death. This disease predominantly affects small airways with acute inflammatory edema epithelial cells, excess mucus production, and bronchospasm. The most commonly involved organisms are Respiratory Syncytial Virus (accounting for 60% of cases), followed by Rhinovirus, Parainfluenza, Metapneumovirus, Influenza, and Adenovirus. Certain factors are associated with a higher risk of severe bronchiolitis, such as prematurity, chronic lung disease, cardiac disease, immunodeficiency, neuromuscular disease, and Down syndrome. Diagnosis of bronchiolitis relies on a constellation of clinical manifestations, including respiratory distress and wheezing preceded by viral upper respiratory tract prodrome in children under two years of age. Common manifestations of bronchiolitis are rhinorrhea, cough, wheezing, tachypnea, and increased work of breathing, including nasal flaring, retractions, and grunting. Management of bronchiolitis is mainly supportive, aiming at maintaining adequate oxygenation and hydration. Given the high burden of bronchiolitis and the lack of specific treatment, studies have investigated several therapeutic options. One of these potential therapies is vitamin D. Vitamin D is a fat-soluble vitamin that is mainly formed in the skin after exposure to ultraviolet rays, while less than 10% is obtained from dietary sources. Besides regulation of calcium and phosphorus homeostasis, vitamin D plays an important role in enhancing mucosal immune defense, decreasing excessive inflammation, and increasing mucociliary clearance. Vitamin D deficiency is common among children, particularly in developing countries, and has been linked to an increased risk of several diseases, including bronchiolitis, pneumonia, and otitis media. Experimental studies have shown that vitamin D reduces inflammation of epithelial cells in airways infected with Respiratory Syncytial Virus and confers antiviral effects. Furthermore, several studies have shown lower serum vitamin D levels in hospitalized children with bronchiolitis. However, studies on the efficacy of Vitamin D supplementation for children with bronchiolitis are scarce with inconsistent findings. In this study, we aim to evaluate the efficacy of vitamin D supplementation in children with bronchiolitis.
Interventions
DRUGVitamin D3
A single dose of intramuscular 200,000 IU vitamin D3 within 24 hours of admission
Sponsors
Sohag University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Two groups of children with bronchiolitis: Study group: will receive a single dose of intramuscular 200,000 IU vitamin D3 within 24 hours of admission. Control group: will receive the standard recommended dose of vitamin D3 as 400 IU/day orally
Eligibility
Sex/Gender
ALL
Age
3 Months to 24 Months
Healthy volunteers
No
Inclusion criteria
* Age between 3 to 24 months. * Clinical diagnosis of first episode of bronchiolitis * First 24 hours of admission. * Stable or decreasing requirement for oxygen on 2 measurements 2 hours apart. * Pulse rate less than 180 beat/minute. * Respiratory rate less than 80 breath/min. * Oxygen supplementation \< 40% Fraction of inspired oxygen or \< 2 L/min by nasal prong * Not on high flow nasal cannula, continuous positive airway pressure, or mechanical ventilation at the time of enrollment.
Exclusion criteria
.• History of previous episodes of wheezing. * History of apnea * Need for positive pressure support or high flow nasal cannula at the time of enrollment. * Chronic lung disease (requiring home oxygen, or pulmonary hypertension) * Cardiac disease (cyanotic, hemodynamically significant \[requiring diuretics\], or pulmonary hypertension). * Neuromuscular disease. * Metabolic disease. * Immunodeficiency. * Chromosomal abnormalities. * Craniofacial malformation * Hemoglobinopathy. * Hypercalcemia * Chromosomal abnormalities * Use of large doses of vitamin D (\> 400 IU/day) in the last month.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Time from randomization to discharge | 4 weeks | Time from randomization to hospital discharge (in hours) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Time from randomization to discontinuation of intravenous fluids | 4 weeks | Time from randomization to discontinuation of intravenous fluids (in hours) |
| Time from randomization to meeting discharge criteria | 4 weeks | Time from randomization to meeting hospital discharge criteria (in hours) |
| Time from hospital admission to discharge | 4 weeks | Time from hospital admission to discharge (in hours) |
| Blood level of 25-hydroxycholecalciferol | On day 3 after randomization | Blood level of 25-hydroxycholecalciferol |
| Serum level of ionized calcium | On day 3 after randomization | Serum level of ionized calcium |
| Time from randomization to discontinuation of oxygen therapy | 4 weeks | Time from randomization to discontinuation of oxygen therapy (in hours) |
| Intubation | 4 weeks | Proportion of patients who underwent endotracheal intubation |
| Mortality | 4 weeks | Proportion of patients who died during hospital admission |
| Bronchodilator therapy | 4 weeks | Proportion of patients who received bronchodilator therapy |
| Systemic steroids | 4 weeks | Proportion of patients who received systemic steroids |
| Admission to pediatric intensive care unit | 4 weeks | Proportion of patients admitted to pediatric intensive care unit |
Countries
Egypt
Outcome results
None listed